Literature DB >> 12541134

Tumour-specific activation of the sodium/iodide symporter gene under control of the glucose transporter gene 1 promoter (GTI-1.3).

Stephanie Sieger1, Shiming Jiang, Frank Schönsiegel, Helmut Eskerski, Wolfgang Kübler, Annette Altmann, Uwe Haberkorn.   

Abstract

Targeted transfer of a functionally active sodium iodide symporter (NIS) into tumour cells may be used for radioiodine therapy of cancer. Therefore, we investigated radioiodine uptake in a hepatoma cell line in vitro and in vivo after transfer of the sodium iodide symporter ( hNIS) gene under the control of a tumour-specific regulatory element, the promoter of the glucose transporter 1 gene (GTI-1.3). Employing a self-inactivating bicistronic retroviral vector for the transfer of the hNIS and the hygromycin resistance genes, rat Morris hepatoma (MH3924A) cells were infected with retroviral particles and hNIS-expressing cell lines were generated by hygromycin selection. (125)I(-) uptake and efflux were determined in genetically modified and wild type hepatoma cells. In addition, the iodide distribution in rats bearing wild type and genetically modified hepatomas was monitored. hNIS-expressing MH3924A cell lines accumulated up to 30 times more iodide than wild type hepatoma cells, with a maximal iodide uptake after 30 min incubation time. Competition experiments in the presence of sodium perchlorate revealed a decrease in the iodide uptake (80-84% decrease). Moreover, ouabain led to a loss of accumulated I(-) (81% decrease) whereas 4,4'-diisothiocyano-2,2'-disulphonic acid stilbene (DIDS) increased the I(-) uptake into cells (87% increase). However, a rapid efflux of the radioactivity (70%) was observed 20 min after (125)I(-)-containing medium had been replaced by non-radioactive medium. Lithium had no significant effect on iodide efflux. In rats, the hNIS-expressing tumours accumulated 22 times more iodide than the contralateral wild type tumour. In accordance with the in vitro data, we also observed a rapid efflux of the radioactivity out of the tumour in vivo. Dosimetric calculations resulted in an absorbed dose of 85 mGy in the wild type tumour and 830 mGy in the hNIS-expressing tumour after administration of 18.5 MBq (131)I. In conclusion, transduction of the hNIS gene under the control of the GLUT1 promoter element induces iodide transport in Morris hepatoma cells in vitro and in vivo. However, for therapeutic application additional conditions need to be defined which inhibit the iodide efflux out of the tumour cells.

Entities:  

Mesh:

Substances:

Year:  2003        PMID: 12541134     DOI: 10.1007/s00259-002-1099-4

Source DB:  PubMed          Journal:  Eur J Nucl Med Mol Imaging        ISSN: 1619-7070            Impact factor:   9.236


  40 in total

Review 1.  Genetics of retroviral integration.

Authors:  S P Goff
Journal:  Annu Rev Genet       Date:  1992       Impact factor: 16.830

2.  Iodide uptake and experimental 131I therapy in transplanted undifferentiated thyroid cancer cells expressing the Na+/I- symporter gene.

Authors:  H Shimura; K Haraguchi; A Miyazaki; T Endo; T Onaya
Journal:  Endocrinology       Date:  1997-10       Impact factor: 4.736

3.  Over-expression of facilitative glucose transporter genes in human cancer.

Authors:  T Yamamoto; Y Seino; H Fukumoto; G Koh; H Yano; N Inagaki; Y Yamada; K Inoue; T Manabe; H Imura
Journal:  Biochem Biophys Res Commun       Date:  1990-07-16       Impact factor: 3.575

4.  An improved retroviral vector for assaying promoter activity. Analysis of promoter interference in pIP211 vector.

Authors:  K Nakajima; K Ikenaka; K Nakahira; N Morita; K Mikoshiba
Journal:  FEBS Lett       Date:  1993-01-04       Impact factor: 4.124

5.  Transfer of the human NaI symporter gene enhances iodide uptake in hepatoma cells.

Authors:  U Haberkorn; M Henze; A Altmann; S Jiang; I Morr; M Mahmut; P Peschke; W Kübler; J Debus; M Eisenhut
Journal:  J Nucl Med       Date:  2001-02       Impact factor: 10.057

6.  Distribution of the glucose transporters in human brain tumors.

Authors:  T Nishioka; Y Oda; Y Seino; T Yamamoto; N Inagaki; H Yano; H Imura; R Shigemoto; H Kikuchi
Journal:  Cancer Res       Date:  1992-07-15       Impact factor: 12.701

7.  Adenovirus-mediated transfer of the thyroid sodium/iodide symporter gene into tumors for a targeted radiotherapy.

Authors:  A Boland; M Ricard; P Opolon; J M Bidart; P Yeh; S Filetti; M Schlumberger; M Perricaudet
Journal:  Cancer Res       Date:  2000-07-01       Impact factor: 12.701

8.  The src oncogene can regulate a human glucose transporter expressed in chicken embryo fibroblasts.

Authors:  M K White; M J Weber
Journal:  Mol Cell Biol       Date:  1990-04       Impact factor: 4.272

9.  The use of lithium in the treatment of thyrotoxicosis.

Authors:  R Temple; M Berman; J Robbins; J Wolff
Journal:  J Clin Invest       Date:  1972-10       Impact factor: 14.808

10.  Establishment of radioactive astatine and iodine uptake in cancer cell lines expressing the human sodium/iodide symporter.

Authors:  T Petrich; H-J Helmeke; G J Meyer; W H Knapp; E Pötter
Journal:  Eur J Nucl Med Mol Imaging       Date:  2002-04-11       Impact factor: 9.236

View more
  14 in total

1.  Baculovirus vector-mediated transfer of NIS gene into colon tumor cells for radionuclide therapy.

Authors:  Hong-Yan Yin; Xiang Zhou; Hai-Fei Wu; Biao Li; Yi-Fan Zhang
Journal:  World J Gastroenterol       Date:  2010-11-14       Impact factor: 5.742

Review 2.  The biology of the sodium iodide symporter and its potential for targeted gene delivery.

Authors:  Mohan Hingorani; Christine Spitzweg; Georges Vassaux; Kate Newbold; Alan Melcher; Hardev Pandha; Richard Vile; Kevin Harrington
Journal:  Curr Cancer Drug Targets       Date:  2010-03       Impact factor: 3.428

Review 3.  Non-invasive Reporter Gene Imaging of Cell Therapies, including T Cells and Stem Cells.

Authors:  Candice Ashmore-Harris; Madeleine Iafrate; Adeel Saleem; Gilbert O Fruhwirth
Journal:  Mol Ther       Date:  2020-03-20       Impact factor: 11.454

4.  Efficacy of 99mTc pertechnetate and 131I radioisotope therapy in sodium/iodide symporter (NIS)-expressing neuroendocrine tumors in vivo.

Authors:  Meike L Schipper; Christoph G U Riese; Stephan Seitz; Alexander Weber; Martin Béhé; Tino Schurrat; Nils Schramm; Boris Keil; Heiko Alfke; Thomas M Behr
Journal:  Eur J Nucl Med Mol Imaging       Date:  2006-12-08       Impact factor: 9.236

5.  The potential of 211Astatine for NIS-mediated radionuclide therapy in prostate cancer.

Authors:  Michael J Willhauck; Bibi-Rana Sharif Samani; Ingo Wolf; Reingard Senekowitsch-Schmidtke; Hans-Jürgen Stark; Geerd J Meyer; Wolfram H Knapp; Burkhard Göke; John C Morris; Christine Spitzweg
Journal:  Eur J Nucl Med Mol Imaging       Date:  2008-04-11       Impact factor: 9.236

Review 6.  PET-based molecular imaging in neuroscience.

Authors:  A H Jacobs; H Li; A Winkeler; R Hilker; C Knoess; A Rüger; N Galldiks; B Schaller; J Sobesky; L Kracht; P Monfared; M Klein; S Vollmar; B Bauer; R Wagner; R Graf; K Wienhard; K Herholz; W D Heiss
Journal:  Eur J Nucl Med Mol Imaging       Date:  2003-05-23       Impact factor: 9.236

Review 7.  Imaging of T-cell Responses in the Context of Cancer Immunotherapy.

Authors:  Zebin Xiao; Ellen Puré
Journal:  Cancer Immunol Res       Date:  2021-05       Impact factor: 11.151

8.  Normalisation to blood activity is required for the accurate quantification of Na/I symporter ectopic expression by SPECT/CT in individual subjects.

Authors:  Peggy Richard-Fiardo; Philippe R Franken; Audrey Lamit; Robert Marsault; Julien Guglielmi; Béatrice Cambien; Fanny Graslin; Sabine Lindenthal; Jacques Darcourt; Thierry Pourcher; Georges Vassaux
Journal:  PLoS One       Date:  2012-03-21       Impact factor: 3.240

9.  [18F]tetrafluoroborate-PET/CT enables sensitive tumor and metastasis in vivo imaging in a sodium iodide symporter-expressing tumor model.

Authors:  S Diocou; A Volpe; M Jauregui-Osoro; M Boudjemeline; K Chuamsaamarkkee; F Man; P J Blower; T Ng; G E D Mullen; G O Fruhwirth
Journal:  Sci Rep       Date:  2017-04-19       Impact factor: 4.379

10.  The glial fibrillary acidic protein promoter directs sodium/iodide symporter gene expression for radioiodine therapy of malignant glioma.

Authors:  Wei Li; Jian Tan; Peng Wang; Ning Li; Fuhai Zhang
Journal:  Oncol Lett       Date:  2012-12-03       Impact factor: 2.967

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.